©The Author(s) 2018.
World J Gastroenterol. Feb 14, 2018; 24(6): 716-724
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.716
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.716
Table 2 Patient and procedure characteristics by study year: 2009 is prior to split dosing, and 2011 is after split dosing
| Characteristic | 2009 (n = 1987) | 2011 (n = 2238) | Total (n = 4225) | P value1 |
| Age, yr | ||||
| ≤ 55 | 1096 (55.2) | 1311 (58.6) | 2407 | < 0.001 |
| 55-65 | 606 (30.5) | 674 (30.1) | 1,280 | |
| 65-75 | 233 (11.7) | 253 (11.3) | 486 | |
| ≥ 75 | 52 (2.6) | 0 (0) | 52 | |
| Female | 1099 (55.3) | 1182 (52.8) | 2281 | 0.100 |
| Race/ethnicity | ||||
| White or Hispanic | 1652 (83.1) | 1846 (82.5) | 3498 | < 0.001 |
| Black | 131 (6.6) | 160 (7.1) | 291 | |
| Asian | 128 (6.4) | 129 (5.8) | 257 | |
| Other | 20 (1.0) | 100 (4.5) | 120 | |
| BMI (kg/m2), mean (SD) | 1871 (94.2) | 2213 (98.9) | 4084 | 0.610 |
| Current narcotics2 use | ||||
| Yes | 131 (6.6) | 163 (7.3) | 294 | 0.360 |
| No | 1856 (93.4) | 2066 (92.3) | 3922 | |
| Current TCA use | ||||
| Yes | 47 (2.4) | 31 (1.4) | 78 | 0.020 |
| No | 1940 (97.6) | 2198 (98.2) | 4138 | |
| Type II diabetes | ||||
| Yes | 164 (8.3) | 201 (9.0) | 365 | 0.400 |
| No | 1823 (91.7) | 2037 (91.0) | 3860 | |
| Bowel preparation quality | ||||
| Adequate or excellent | 592 (30.6) | 886 (39.6) | 1478 | < 0.001 |
| Good | 1044 (54.0) | 1048 (46.9) | 2092 | |
| Fair | 209 (10.8) | 189 (8.5) | 398 | |
| Inadequate or poor | 89 (4.6) | 113 (5.1) | 202 | |
| Polyp presence | ||||
| Yes | 745 (37.5) | 807 (36.1) | 1552 | 0.330 |
| No | 1242 (62.5) | 1431 (63.9) | 2673 | |
| Preparation type | ||||
| 8L PEG | 5 (0.3) | 17 (0.8) | 22 | < 0.001 |
| MiraLAX/Gatorade | 541 (28.3) | 1228 (57.1) | 1769 | |
| 4L PEG, GoLYTELY, NuLYTELY, Colyte, TriLyte | 1015 (53.1) | 771 (35.9) | 1786 | |
| Half-Lytely,Osmoprep, Moviprep, and others | 352 (18.4) | 133 (6.2) | 485 | |
| Preparation type | ||||
| MiraLAX/Gatorade | 541 (28.3) | 1228 (57.1) | 1769 | < 0.001 |
| 4L PEG, GoLYTELY, NuLYTELY, Colyte, TriLyte | 1015 (53.1) | 771 (35.9) | 1786 | |
| Half-Lytely, Osmoprep, Moviprep, and others | 357 (18.7) | 150 (7.0) | 507 | |
| GI fellow presence | ||||
| Yes | 187 (9.4) | 303 (13.5) | 490 | < 0.001 |
| No | 1800 (90.6) | 1935 (86.5) | 3735 |
- Citation: Menees SB, Kim HM, Schoenfeld P. Split-dose bowel preparation improves adequacy of bowel preparation and gastroenterologists’ adherence to National Colorectal Cancer Screening and Surveillance Guidelines. World J Gastroenterol 2018; 24(6): 716-724
- URL: https://www.wjgnet.com/1007-9327/full/v24/i6/716.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i6.716